Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: NRugg who wrote (1754)	2/15/2004 9:47:38 AM
From: Art Bechhoefer	Respond to of 1870

Significant revenue from Genasense will depend on how soon Genta's partner Aventis will be able to manufacture and market the drug in quantity--perhaps within a matter of months after approval. However, the real problem is that Genta may have to raise money before that time. The only way they can do this is to work out some arrangement with Aventis or other interested companies, or issue more stock, which will dilute future earnings. The good news is that approval of Genasense as part of a treatment for melanoma will pave the way for its use in other applications, such as metastizing breast cancer. Art

To: NRugg who wrote (1754)	3/1/2004 10:55:07 AM
From: bob zagorin	Respond to of 1870

Genta to Present at Lehman Brothers Healthcare Conference (March 3) BERKELEY HEIGHTS, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced that it will present at the Lehman Brothers Healthcare Conference in Miami Beach, FL. William P. Keane, Genta's Vice President and Chief Financial Officer, will provide an update on the Company's products and development programs on Wednesday, March 3, 2004 at 4:15 pm EST. ADVERTISEMENT A live audio webcast of the presentation can be accessed through Genta's Investor Relations site at: genta.com. A replay will be available approximately 24 hours following the presentation and will be available for 30 days thereafter. About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA and DNA-based medicines) and small molecules. Genasense(TM) (oblimersen sodium), the Company's lead compound from its oligonucleotide program, is being developed with Aventis and is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite(TM) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: www.genta.com.